Last reviewed · How we verify
PENG
PENG, marketed by Medipol University, is a small molecule therapy with a key composition patent expiring in 2028. Its mechanism of interacting with specific biological molecules offers a targeted therapeutic approach, positioning it as a precise treatment option. The primary risk is the patent expiry in 2028, which could lead to increased competition from generics.
At a glance
| Generic name | PENG |
|---|---|
| Sponsor | Medipol University |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- PENG Block With or Without PPD Block for Postoperative Analgesia After Total Hip Arthroplasty (NA)
- Comparison of Femoral Nerve Block and Combined PENG Plus Femoral Nerve Block in Geriatric Hip Surgery (NA)
- Pericapsular Nerve Group (PENG) Block Combined With Lateral Femoral Cutaneous Nerve (LFCN) Block or Wound Infiltration for Postoperative Analgesia in Anterior Approach Total Hip Arthroplasty: A Randomized Controlled Trial (NA)
- Shoulder Pericapsular Block Versus Interscalene Block in Arthroscopic Shoulder Surgery (NA)
- PENG Block & PENG PRF
- PENG Block Optimization: Volume and Dexamethasone Effects (PHASE4)
- The Effect of Dexamethasone Administration Route in PENG Block for Pediatric Hip Surgery (PHASE4)
- PENG Block Variants With Dexamethasone and Dexmedetomidine in Older Adults (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- PENG CI brief — competitive landscape report
- PENG updates RSS · CI watch RSS
- Medipol University portfolio CI